Aurobindo Pharma Ltd
Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.(Source : 202003 Annual Report Page No:159)
- Market Cap ₹ 70,805 Cr.
- Current Price ₹ 1,208
- High / Low ₹ 1,593 / 958
- Stock P/E 19.4
- Book Value ₹ 527
- Dividend Yield 0.37 %
- ROCE 14.1 %
- ROE 11.5 %
- Face Value ₹ 1.00
Pros
- Company has been maintaining a healthy dividend payout of 17.0%
Cons
- The company has delivered a poor sales growth of 8.19% over past five years.
- Company has a low return on equity of 10.3% over last 3 years.
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Part of BSE 500 BSE Healthcare BSE 200 BSE Dollex 200 Nifty 500
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
5,842 | 8,089 | 12,103 | 13,772 | 14,910 | 16,463 | 19,564 | 23,099 | 24,775 | 23,455 | 24,855 | 29,002 | 30,295 | |
4,965 | 5,951 | 9,524 | 10,579 | 11,469 | 12,691 | 15,612 | 18,249 | 19,497 | 19,060 | 21,148 | 23,176 | 23,852 | |
Operating Profit | 877 | 2,137 | 2,579 | 3,193 | 3,441 | 3,772 | 3,952 | 4,849 | 5,278 | 4,396 | 3,707 | 5,826 | 6,443 |
OPM % | 15% | 26% | 21% | 23% | 23% | 23% | 20% | 21% | 21% | 19% | 15% | 20% | 21% |
12 | 18 | 81 | 200 | 115 | 105 | 70 | 166 | 3,195 | 152 | 291 | 366 | 533 | |
Interest | 267 | 310 | 160 | 257 | 67 | 78 | 263 | 305 | 74 | 49 | 140 | 290 | 389 |
Depreciation | 249 | 313 | 333 | 392 | 428 | 558 | 668 | 967 | 1,055 | 1,127 | 1,245 | 1,522 | 1,564 |
Profit before tax | 374 | 1,533 | 2,168 | 2,744 | 3,061 | 3,241 | 3,091 | 3,743 | 7,344 | 3,373 | 2,612 | 4,380 | 5,024 |
Tax % | 22% | 24% | 28% | 26% | 25% | 25% | 24% | 24% | 27% | 22% | 26% | 28% | |
291 | 1,169 | 1,571 | 2,024 | 2,301 | 2,423 | 2,364 | 2,844 | 5,334 | 2,647 | 1,928 | 3,169 | 3,582 | |
EPS in Rs | 5.05 | 20.12 | 26.98 | 34.61 | 39.29 | 41.36 | 40.36 | 48.56 | 91.05 | 45.20 | 32.90 | 54.15 | 61.13 |
Dividend Payout % | 15% | 7% | 8% | 7% | 6% | 6% | 6% | 6% | 4% | 20% | 23% | 8% |
Compounded Sales Growth | |
---|---|
10 Years: | 14% |
5 Years: | 8% |
3 Years: | 5% |
TTM: | 12% |
Compounded Profit Growth | |
---|---|
10 Years: | 11% |
5 Years: | 6% |
3 Years: | -1% |
TTM: | 54% |
Stock Price CAGR | |
---|---|
10 Years: | 9% |
5 Years: | 22% |
3 Years: | 20% |
1 Year: | 18% |
Return on Equity | |
---|---|
10 Years: | 16% |
5 Years: | 13% |
3 Years: | 10% |
Last Year: | 12% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 29 | 29 | 29 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 58 |
Reserves | 2,577 | 3,721 | 5,127 | 7,229 | 9,313 | 11,622 | 13,832 | 16,766 | 21,871 | 24,517 | 26,781 | 29,784 | 30,820 |
3,435 | 3,769 | 4,451 | 5,041 | 3,364 | 4,770 | 6,967 | 5,826 | 5,339 | 2,851 | 5,286 | 6,648 | 8,427 | |
1,232 | 1,970 | 3,303 | 3,568 | 3,464 | 4,492 | 5,414 | 6,113 | 6,147 | 6,211 | 7,379 | 8,227 | 8,789 | |
Total Liabilities | 7,273 | 9,490 | 12,910 | 15,896 | 16,200 | 20,942 | 26,271 | 28,765 | 33,416 | 33,638 | 39,505 | 44,717 | 48,094 |
2,639 | 2,722 | 3,706 | 4,180 | 4,834 | 6,521 | 8,475 | 9,396 | 9,374 | 10,532 | 11,024 | 14,493 | 15,436 | |
CWIP | 219 | 310 | 420 | 848 | 1,458 | 1,583 | 1,668 | 1,986 | 3,062 | 3,747 | 5,390 | 3,869 | 3,497 |
Investments | 22 | 20 | 20 | 123 | 246 | 312 | 360 | 555 | 591 | 997 | 543 | 372 | 325 |
4,393 | 6,439 | 8,765 | 10,745 | 9,662 | 12,527 | 15,768 | 16,827 | 20,390 | 18,362 | 22,549 | 25,983 | 28,837 | |
Total Assets | 7,273 | 9,490 | 12,910 | 15,896 | 16,200 | 20,942 | 26,271 | 28,765 | 33,416 | 33,638 | 39,505 | 44,717 | 48,094 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
275 | 646 | 1,237 | 1,420 | 3,279 | 1,955 | 1,651 | 4,381 | 3,329 | 5,016 | 2,387 | 2,435 | |
-246 | -819 | -1,017 | -1,446 | -1,787 | -1,927 | -2,904 | -1,563 | 597 | -3,211 | -3,971 | -4,242 | |
108 | 118 | 93 | 365 | -1,915 | 864 | 1,919 | -1,947 | -1,365 | -2,969 | 1,814 | 800 | |
Net Cash Flow | 137 | -55 | 313 | 340 | -424 | 892 | 666 | 871 | 2,561 | -1,164 | 230 | -1,007 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 100 | 119 | 107 | 122 | 68 | 68 | 64 | 68 | 52 | 62 | 66 | 61 |
Inventory Days | 235 | 240 | 239 | 240 | 246 | 317 | 304 | 289 | 333 | 272 | 275 | 284 |
Days Payable | 118 | 137 | 136 | 146 | 122 | 128 | 107 | 97 | 103 | 97 | 125 | 129 |
Cash Conversion Cycle | 217 | 222 | 210 | 217 | 191 | 257 | 260 | 260 | 282 | 237 | 216 | 216 |
Working Capital Days | 171 | 162 | 126 | 141 | 122 | 139 | 148 | 120 | 124 | 120 | 119 | 120 |
ROCE % | 11% | 27% | 27% | 27% | 25% | 23% | 18% | 19% | 18% | 13% | 9% | 14% |
Documents
Announcements
-
The Company Has Received An Order From The Additional Commissioner (ST), Appellate Authority, Vijayawada, Andhra Pradesh, Passed Under Relevant Provisions Of The Central Goods And Services Tax Act, 2017 And APGST Act, 2017
9h - Company received GST order demanding reversal of ITC.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
9h - CuraTeQ Biologics receives positive opinion for biosimilar Zefylti.
-
Announcement under Regulation 30 (LODR)-Cessation
10h - Retirement of Mrs. Savita Mahajan as Independent Director.
-
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015.
2d - Theranym allotted shares, ceasing to be wholly owned.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
5 Dec - Eugia Pharma receives USFDA approval for Pazopanib Tablets.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2013
from nse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
Concalls
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
Jun 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Feb 2023TranscriptNotesPPT
-
Feb 2023TranscriptNotesPPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Jun 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Sep 2021Transcript PPT
-
Aug 2021TranscriptNotesPPT
-
Jun 2021Transcript PPT
-
Feb 2021Transcript PPT
-
Nov 2020Transcript PPT
-
Aug 2020Transcript PPT
-
Jun 2020Transcript PPT
-
Feb 2020Transcript PPT
-
Feb 2020TranscriptNotesPPT
-
Jan 2020TranscriptNotesPPT
-
Nov 2019Transcript PPT
-
Nov 2019TranscriptNotesPPT
-
Aug 2019TranscriptPPT
-
Aug 2019Transcript PPT
-
Aug 2019TranscriptNotesPPT
-
Jun 2019Transcript PPT
-
May 2019TranscriptNotesPPT
-
Mar 2019Transcript PPT
-
Feb 2019Transcript PPT
-
Feb 2019TranscriptNotesPPT
-
Jan 2019TranscriptNotesPPT
-
Nov 2018Transcript PPT
-
Nov 2018TranscriptNotesPPT
-
Sep 2018Transcript PPT
-
Sep 2018Transcript PPT
-
Aug 2018TranscriptNotesPPT
-
Aug 2018TranscriptNotesPPT
-
Jun 2018Transcript PPT
-
May 2018TranscriptNotesPPT
-
Mar 2018Transcript PPT
-
Feb 2018TranscriptNotesPPT
-
Feb 2018TranscriptNotesPPT
-
Feb 2018TranscriptNotesPPT
-
Jan 2018TranscriptNotesPPT
-
Nov 2017Transcript PPT
-
Nov 2017TranscriptNotesPPT
-
Sep 2017TranscriptNotesPPT
-
Aug 2017Transcript PPT
-
Aug 2017TranscriptNotesPPT
-
Jun 2017TranscriptNotesPPT
-
Jun 2017TranscriptNotesPPT
-
Jun 2017TranscriptNotesPPT
-
May 2017TranscriptNotesPPT
-
Mar 2017Transcript PPT
-
Feb 2017TranscriptNotesPPT
-
Feb 2017TranscriptNotesPPT
-
Nov 2016Transcript PPT
-
Nov 2016TranscriptNotesPPT
-
Sep 2016TranscriptNotesPPT
-
Sep 2016Transcript PPT
-
Aug 2016TranscriptNotesPPT
-
Aug 2016TranscriptNotesPPT
-
Jun 2016Transcript PPT
-
Feb 2016Transcript PPT
Leading Pharmaceutical company [1]
Aurobindo Pharma is India’s second-largest pharma company & Largest generics company in the US (by Rx dispensed). It is also the largest generic company in the US and is amongst the top 10 generic companies in seven out of 11 countries in Europe.[2]The Company is among the top 5 listed pharmaceutical companies in India by FY22 revenues [3]